At MacuDopa, we are committed to providing the best service and tailored information to our customers worldwide. Our UK and USA websites are designed to cater to the unique needs and regulatory landscapes of each region.
The Difference in Regulations
In the UK, MacuDopa is classified as a novel food by the Medicines and Healthcare products Regulatory Agency (MHRA). This means we are not permitted to make health claims or promote the potential benefits of MacuDopa as a treatment for Parkinson's Disease or any other condition. These strict guidelines are in place to ensure consumer protection and compliance with European and UK food standards.
On the other hand, in the USA, we operate within a different regulatory framework, which allows for more flexibility in sharing educational information and research findings. This enables us to provide deeper insights into how MacuDopa can support neurological health.
What This Means for You
On our UK site, you’ll find clear, compliant product information without health claims, reflecting MHRA regulations.
On our USA site, we can share more details about the science behind MacuDopa, including its role in supporting motor and non-motor symptoms, as permitted under U.S. guidelines.
Our Commitment to You
Regardless of location, we encourage all our customers to discuss MacuDopa with their healthcare provider or neurologist to ensure it fits seamlessly into their treatment plan.
By maintaining separate websites, we ensure transparency, regulatory compliance, and the best possible experience for our customers in both the UK and the USA. If you have any questions, we’re here to help!